Corbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update November 10, 2016
Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union October 18, 2016
Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis October 13, 2016
Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation September 28, 2016
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis September 12, 2016
Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update August 15, 2016
Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 July 6, 2016
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016 June 17, 2016
Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis June 16, 2016
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update May 16, 2016
Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis April 12, 2016
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND March 31, 2016
Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update March 29, 2016
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus March 7, 2016
Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016 February 1, 2016
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015 November 23, 2015
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis October 20, 2015
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis October 15, 2015
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis October 7, 2015
